Loading...
•
Dec 31, 2024
iBio Q2 2025 Earnings Report
iBio reported financial results for the second quarter ended December 31, 2024.
Key Takeaways
iBio reported revenue of $0.2 million for services provided to a collaborative partner and a net loss of $4.4 million, or $0.48 per share, for the second quarter ended Dec. 31, 2024. The company also highlighted advancements in its preclinical pipeline and key board appointments.
Discovered a novel antibody targeting activin E in collaboration with AstralBio.
Expanded iBio’s cardiometabolic and obesity program with IBIO-600, the long-acting anti-myostatin antibody in-licensed from AstralBio.
Initiated a bispecific antibody program targeting myostatin/activin A to promote weight loss, muscle preservation, and prevent weight regain with plans for clinical investigation in obesity and cardiometabolic disorders in 2026.
Strengthened the Board of Directors with the appointments of biotech industry veterans David Arkowitz and António Parada.
iBio
iBio
Forward Guidance
iBio is focused on leveraging its AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity.
Positive Outlook
- Potential for IBIO-600 to be best-in-class.
- Leveraging iBio’s AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity.
- Offering hope for more effective, targeted therapies addressing the underlying causes of these conditions while improving overall metabolic health and quality of life.
- IBIO-600’s potential for an extended half-life.
- The creation of a pipeline of breakthrough antibody treatments to address significant unmet medical needs.
Challenges Ahead
- iBio’s ability to leverage its AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity.
- iBio's ability to extend the half-life of IBIO-600.
- iBio's ability to advance as a clinical-stage biotech and commence a clinical investigation in obesity and cardiometabolic disorders in 2026.
- iBio's ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs.
- iBio's ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine